Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta - Wynn, D; Kaufman, M; Montalban, X (Lancet Neurol, 2010)
, et al; CHOICE investigators.